NDA 018124 · Sun Pharm Inds INC
Cis-Mdp
Technetium Tc-99m Medronate Kit · Injection · Radioactive Diagnostic Agent
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Aug 29, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
4
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 11, 2025.
INDICATIONS AND USAGE: Technetium Tc 99m Medronate Injection may be used as a bone imaging agent to delineate areas of altered osteogenesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 29, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- CIS-MDP · TECHNETIUM TC-99M MEDRONATE KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Medronate Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus2
- erythema1
- hypersensitivity1
- palpitations1
- rash1
- throat tightness1
- ulcer1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2015 | 3 |
Recalls
1 FDA enforcement reports for this application.
Jun 6, 2018 · Class II · Terminated
Lack of assurance of sterility: Technetium TC-99M Medronate Kit has a reported breach of sterility.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.